Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Morel‐Maroger, J. Méry, D. Droz, M. Godin, P. Verroust, O. Kourilsky, G. Richet (1976)
The course of lupus nephritis: contribution of serial renal biopsies.Advances in nephrology from the Necker Hospital, 6
D. Boumpas, H. Austin, E. Vaughan, Cheryl Yarboro, J. Klippel, J. Balow (1993)
Risk for Sustained Amenorrhea in Patients with Systemic Lupus Erythematosus Receiving Intermittent Pulse Cyclophosphamide TherapyAnnals of Internal Medicine, 119
G. Illei, K. Takada, D. Parkin, H. Austin, M. Crane, Cheryl Yarboro, E. Vaughan, T. Kuroiwa, C. Danning, J. Pando, A. Steinberg, M. Gourley, J. Klippel, J. Balow, D. Boumpas (2002)
Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.Arthritis and rheumatism, 46 4
W. Lloyd, P. Schur (1981)
Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE).Medicine, 60 3
C. Ponticelli, G. Moroni (1998)
Flares in lupus nephritis: Incidence, impact on renal survival and managementLupus, 7
E. Borg, G. Horst, E. Hummel, P. Limburg, C. Kallenberg (1990)
Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.Arthritis and rheumatism, 33 5
G. Moroni, Silvana Quaglini, Massimo Maccario, G. Banfi, C. Ponticelli (1996)
"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.Kidney international, 50 6
D. Boumpas, H. Austin, J. Balow, E. Vaughan, Cheryl Yarboro, J. Klippel, A. Steinberg (1992)
Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritisThe Lancet, 340
R. Cervera, M. Khamashta, J. Font, G. Sebastiani, A. Gil, P. Lavilla, A. Aydintug, A. Jędryka-Góral, E. Ramón, A. Fernández-Nebro, M. Galeazzi, H. Haga, A. Mathieu, F. Houssiau, G. Ruiz‐Irastorza, M. Ingelmo, G. Hughes (1999)
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus.Medicine, 78 3
(1997)
erythemato
M. Mosca, A. Pasquariello, A. Tavoni, L. Moriconi, I. Moneta, M. Innocenti, W. Bencivelli, S. Bombardieri (1997)
Predictors of renal outcome in diffuse proliferative glomerulonephritis in systemic lupus erythematosusLupus, 6
F. Houssiau, C. Vasconcelos, D. D'cruz, G. Sebastiani, Enrique Ed, M. Danieli, D. Abramovicz, D. Blockmans, A. Mathieu, H. Direskeneli, M. Galeazzi, A. Gül, Y. Levy, P. Petera, R. Popović, R. Petrovic, R. Sinico, R. Cattaneo, J. Font, G. Depresseux, J. Cosyns, R. Cervera (2002)
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.Arthritis and rheumatism, 46 8
M. Mosca, W. Bencivelli, R. Neri, A. Pasquariello, V. Batini, R. Puccini, A. Tavoni, S. Bombardieri (2002)
Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis.Kidney international, 61 4
Audrey Ho, L. Magder, S. Barr, M. Petri (2001)
Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.Arthritis and rheumatism, 44 10
E. Ciruelo, Javier Cruz, Ignacio López, J. Gómez-Reino (1996)
Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.Arthritis and rheumatism, 39 12
J. Kobashigawa, L. Miller, D. Renlund, R. Mentzer, E. Alderman, R. Bourge, M. Costanzo, H. Eisen, G. Dureau, R. Ratkovec, M. Hummel, D. Ipe, J. Johnson, A. Keogh, R. Mamelok, D. Mancini, F. Smart, H. Valantine (1998)
A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.Transplantation, 66 4
E. Tan, A. Cohen, J. Fries, A. Masi, D. McShane, N. Rothfield, J. Schaller, N. Talal, R. Winchester (1982)
The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis and rheumatism, 25 11
A. Swaak, L. Aarden, L. Eps, T. Feltkamp (1979)
Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus.Arthritis and rheumatism, 22 3
G. Illei, H. Austin, M. Crane, L. Collins, M. Gourley, Cheryl Yarboro, E. Vaughan, T. Kuroiwa, C. Danning, A. Steinberg, J. Klippel, J. Balow, D. Boumpas (2001)
Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus NephritisAnnals of Internal Medicine, 135
T. Chan, F. Li, C. Tang, R. Wong, G. Fang, Y. Ji, C. Lau, A. Wong, M. Tong, K. Chan, K. Lai (2000)
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.The New England journal of medicine, 343 16
Audrey Ho, S. Barr, L. Magder, M. Petri (2001)
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.Arthritis and rheumatism, 44 10
(1995)
Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.Lancet, 345 8961
We prospectivelyfollowed a cohort of 46 newly diagnosed cases of lupus nephritis (LN) over a mean period of five years in order to determine the renal relapse rate, to identify potential risk factors for relapses, to assess the value of serological tests during flares and to analyse their impact on global outcome. Of the patients 37% experienced at least one renal flare, the first episode occurring after a mean follow-up of 40 months, when most patients were still treated with low-dose glucocorticoidsand azathioprine. Baseline biochemical and pathological data did not differ between relapsing and nonrelapsing patients. Serological findings (low complement and high anti-DNA antibody) were less pronounced at relapse. Moreover, neither a decline in complement nor a rise in anti-DNA antibody titres were observed by the time of renal relapse, compared to immediate pre-flare values. Poor outcomes were observed only in relapsing patients. Taken together, renal relapses in LN patients are common, have a negative impact on outcome, but cannot be readily predicted. These results stress the importance of regular blood and urine examinations in LN patients, even years after the initial episode.
Lupus – SAGE
Published: Jul 2, 2016
Keywords: lupus nephritis,relapses,serology
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.